Evidence map›Paper›PMID 40174917›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

BCG induced innate immune response heterogeneity and susceptibility to pediatric tuberculosis.

Christine Anterasian, Anele Gela, Temwa-Dango Mwambene, Javeed A Shah, Josh Ivie, Kimberly A Dill-McFarland, Willem A Hanekom, Michael C Kiritsy, Christopher M Sassetti, Munyaradzi Musvosvi and 3 more

Abstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Christine AnterasianUniversity of Washington School of Medicine, Seattle, WA, United States.ORCID 0000-0002-9906-5554
Anele GelaSouth African Tuberculosis Vaccine Initiative and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-1473-9204
Temwa-Dango MwambeneSouth African Tuberculosis Vaccine Initiative and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Javeed A ShahUniversity of Washington School of Medicine, Seattle, WA, United States.ORCID 0000-0002-2997-7988
Josh IvieUniversity of Washington School of Medicine, Seattle, WA, United States.
Kimberly A Dill-McFarlandUniversity of Washington School of Medicine, Seattle, WA, United States.ORCID 0000-0003-1481-7065
Willem A HanekomAfrica Health Research Institute (AHRI), KwaZulu-Natal, South Africa.
Michael C KiritsyDepartment of Medicine, Duke University, Durham, NC, United States.ORCID 0000-0001-8364-8088
Christopher M SassettiDepartment of Microbiology and Physiological Systems, UMass Chan Medical School, Worchester, MA, United States.
Munyaradzi MusvosviSouth African Tuberculosis Vaccine Initiative and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.
Mark HatherillSouth African Tuberculosis Vaccine Initiative and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0003-3491-1809
Thomas J ScribaSouth African Tuberculosis Vaccine Initiative and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa.ORCID 0000-0002-0641-1359
Thomas R HawnUniversity of Washington School of Medicine, Seattle, WA, United States.

Funding

Systems Genetics of TuberculosisP01AI132130 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BEHAR, SAMUEL M · 2017 to 2021
$11.2M
Systems Genetics of TuberculosisP01AI181898 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI CHRISTOPHER M SASSETTI · 2024 to 2026
$10.5M
Diseases of Public Health Importance Training GrantT32AI007509 · NIAID · UNIVERSITY OF WASHINGTON · PI LUND, JENNIFER M · 1997 to 2024
$6.3M
Seattle Tuberculosis Research Advancement CenterP30AI168034 · NIAID · UNIVERSITY OF WASHINGTON · PI Rhea N Coler, CHETAN SESHADRI · 2022 to 2026
$6.3M
TOLLIP Deficiency, Immune Dysregulation, and Tuberculosis SusceptibilityR01AI136921 · NIAID · UNIVERSITY OF WASHINGTON · PI SHAH, JAVEED ALI · 2018 to 2022
$2.5M
Pulmonary Innate Immunity & Resistance to Mycobacterium Tuberculosis InfectionK24AI137310 · NIAID · UNIVERSITY OF WASHINGTON · PI HAWN, THOMAS R · 2018 to 2022
$892k
Immunoproteomic mechanisms of human macrophage resistance to Mycobacterium tuberculosis infectionK08AI163381 · NIAID · UNIVERSITY OF WASHINGTON · PI ANTERASIAN, CHRISTINE M · 2021 to 2025
$815k
The impact of mucociliary clearance on Mycobacterium tuberculosis pathogenesisR21AI165961 · NIAID · UNIVERSITY OF WASHINGTON · PI SHAH, JAVEED ALI · 2023 to 2024
$457k
NIAID NIH HHS K08 AI163381NIAID NIH HHS K24 AI137310NIAID NIH HHS P01 AI132130NIAID NIH HHS P01 AI181898NIAID NIH HHS P30 AI168034NIAID NIH HHS R01 AI136921NIAID NIH HHS R21 AI165961NIAID NIH HHS T32 AI007509
6 · The paper itself

Abstract

Although immune responses to bacillus Calmette-Guerin (BCG)-vaccination and susceptibility to pediatric tuberculosis (TB) vary across individuals, the underlying cellular mechanism regulating this heterogeneity is poorly understood. We used a nested case-control study with a 2-yr prospective observation period to examine whether genetic variation is associated with BCG-induced innate immune responses and susceptibility to pediatric TB (N = 134 cases, 516 controls) in BCG-vaccinated infants. Whole blood collected at 10 wk of age from 189 control infants was stimulated with BCG or media and examined with flow cytometry to measure BCG-induced PDL1, CD40, and cytokine expression in myeloid (mDC) and plasmacytoid (pDC) dendritic cells, monocytes, and neutrophils. We used a cellular and clinical GWAS to assess for associations between genetic variants, BCG-induced innate immune responses, and susceptibility to TB. We identified 11 lead genetic variants at genome-wide level significance associated with BCG-induced cytokine and surface expression markers including PDL1 (5 pDCs, 3 mDCs, 1 monocytes), CD40 (1 mDCs), and IL-6 (1 monocytes). An IGLL1 variant (rs2096522) was associated with mDC CD40 expression (P = 1.6e-08) and was also discovered as a significant variant using a gene-based method. In the clinical GWAS, we identified 39 lead variants mapping to 74 genes suggestive of an association with susceptibility to pediatric TB (P < 1e-05), but no variant reached genome-wide significance. One clinical lead variant in the PDE8A region (rs1023844, P = 9.6e-07) was also an eQTL and associated with BCG-induced monocyte PDL1 expression. In summary, we identified genetic variants associated with heterogeneity in infant BCG-induced innate immune responses with potential immunoregulatory mechanisms.

Indexed as

BCG VaccineImmunity, InnateTuberculosisB7-H1 AntigenCase-Control StudiesCD40 AntigensCytokinesDendritic CellsFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansInfantMaleMonocytesPolymorphism, Single NucleotideB7-H1 AntigenBCG VaccineCD274 protein, humanCD40 AntigensCytokinesBCGgeneticsinnate immunitymycobacteria

Identifiers

PMID40174917
PMCPMC12124979

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.